An evaluation of exercises for the development of word recognition and word meaning in grade five

Thesis (Ed.M.)--Boston Universit

An evaluation of exercises for the development of word recognition and word meaning in grade five

Thesis (Ed.M.)--Boston Universit

Sixty original plays for primary grades

Thesis (Ed.M.)--Boston Universit

A Rapid X-ray Flare from Markarian 501

We present X-ray observations of the BL Lacertae (BL Lac) object Markarian 501 (Mrk 501), taken with the Rossi X-ray Timing Explorer in 1998 May as part of a multi-wavelength campaign. The X-ray light curve shows a very rapid flare in which the 2-10 keV flux increased by ~60% in <200 seconds. This rapid rise is followed by a drop-off in the 2-10 keV flux of ~40% in <600 seconds. The 10-15 keV variation in this flare is roughly a factor of two on similar time-scales. During the rise of the flare, the 3-15 keV spectral index hardened from 2.02 +/- 0.03 to 1.87 +/- 0.04, where it remained during the decay of the flare. This is the fastest variation ever seen in X-rays from Mrk 501 and among the fastest seen at any wavelength for this object. The shift in the energy at which the spectral power peaks (from 30 keV during the flare) is also among the most rapid shifts seen from this object. This flare occurs during an emission state (2-10 keV flux approximately 1.2e-10 erg cm^-2 s^-1) that is approximately 25% of the peak flux observed in 1997 April from this object but which is still high compared to its historical average X-ray flux. The variations in the hardness ratio are consistent with the low energy variations leading those at high energies during the development and decay of the flare. This pattern is rare among high frequency peaked BL Lac objects like Mrk 501, but has been seen recently in two other TeV emitting BL Lacs, Mrk 421 and PKS 2155-304. The hard lag is consistent with a flare dominated by the acceleration time-scale for a simple relativistic shock model of flaring.Comment: 11 pages, 3 figures, accepted for publication in Astrophys. J. Letter

A variable neurodegenerative phenotype with polymerase gamma mutation

mtDNA replication and repair, causes mitochondrial diseases including autosomal dominant progressive external ophthalmoplegia (PEO),1 childhood hepato-encephalopathy (Alpers– Huttenlocher syndrome), adult-onset spinocerebellar ataxia, and sensory nerve degeneration with dysarthria and ophthalmoparesis (SANDO)

Pengaruh Bauran Promosi Terhadap Minat Beli Konsumen (Studi Kasus Pada PT. Capella Dinamik Nusantara Ujungbatu)

This research have done in PT. Capella Dinamik Nusantara Ujungbatu, and the purpose of this research is to know the influence promotion mixed towards buying interest customers of PT. Capella Dinamik Nusantara Ujungbatu. Promotion mixed as independent variable (X) while the customers buying interest as dependent variable (Y).The problem of this research is decline realization sales of PT. Capella Dinamik Nusantara Ujungbatu then target unappropriate with realization sales. There has been seen from realization sales percentage which is fluctuated or up and down the purchase of motor cycle for last 5 years. Sample of this research is taken about 96 slovin formula. The data has been obtained from questionnaire and process next to making a test with statistic by SPSS program. The result of the calculation is the promotion mixed has positive effect about 72,5 % towards customers buying interest in PT. Capella Dinamik Nusantara UjungbatuKeywor: Promotio Mixed, Customers Buying Interes

Implications of Recent Controlled Substance Policy Initiatives

Recent legislative and regulatory activity designed to address controlled substance diversion and overuse of narcotics is having a significant impact on prescription drug utilization and patient care in the United States. Although providers and patients are the focus of these new requirements, the designers and implementers of formularies and medication use protocols need to be aware of salient features of these initiatives. Formulary drug product selection, prior authorization procedures and drug utilization strategies should be reconsidered in accordance with the changes in controlled substance oversight. The primary focus of this article involves recent approaches to controlling the illegal acquisition of licit prescriptions, particularly opioid pain relievers (OPR). According to the Centers for Disease Control and Prevention (CDC), in 2008 OPRs were involved in 74% of the 20,000 fatal prescription drug overdoses in the United States. This represents an increase of over 300% since 1999 and these fatalities now exceed death by cocaine and heroin combined. [Interestingly, the death rate varied five-fold by state, largely reflecting different levels of opioid regulation and oversight. They also noted that sales of OPRs quadrupled between 2000 and 2010 and that OPR abuse cost health insurers over $72 billion annually in healthcare costs